4. Severe Outcomes Among Patients with Coronavirus Disease 2019
(COVID-19) — United States, February 12–March 16, 2020. MMWR Morb
Mortal Wkly Rep 2020;
69:343-346
5. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry
depends on ACE2 and TMPRSS2 and is blocked by a clinically proven
protease inhibitor. Cell 2020; 181:271-280.
6. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of
angiotensin-converting enzyme. Cloning and functional expression as a
captopril-insensitive carboxypeptidase. J Biol Chem. 2000;
274:33238–33243.
7. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological
peptides by human angiotensin-converting enzyme-related
carboxypeptidase. J Biol Chem. 2002; 277:14838–14843.
8. Hamming I, Timens W, Bulthuis MLC, et al. Tissue distribution of ACE2
protein, the functional receptor of SARS coronavirus. A first step in
understanding SARS pathogenesis. J Pathol 2004; 203:631-637
9. Ferrario CM, Jessup J, Chappell MC et al. Effect of
angiotensin-converting enzyme inhibitor and angiotensin II receptor
blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005;
111:2605-2610.
10. Campbell DJ, Zeitz CJ, Esler MD et al. Evidence against a major role
for angiotensin converting enzyme-related carboxypeptidase (ACE 2) in
angiotensin peptide metabolism in human coronary circulation. J
Hypertens 2004; 22:1971-1976.
11. Luque M, Martin P, Martell N, et al. Effects of captopril relate to
increased levels of prostacyclin and angiotensin (1-7) in essential
hypertension. J Hypertens 1996; 14:799-805.
12. Yang P, Gu H, Zhao Z, et al. Angiotensin-converting enzyme 2 (ACE2)
mediates influenza H7N9 virus-induced acute lung injury. Sci Rep 2014;
4:7027.
13. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from
2019-nCoV infected patients linked to viral loads and lung injury. Sci
China Life Sci 2020; 63:364-374.
14. Gu H, Xie Z, Li T, et al.
Angiotensin-converting enzyme 2
inhibits lung injury induced by respiratory syncytial virus. Sci Rep
2016; 6:19840.
15. Kuba K, Imayi Y, Rao S, et al. A crucial role of angiotensin
converting enzyme 2 (ACE2) in SARS-coronavirus-induced lung injury. Nat
Med 2005; 11:875-879.
16. Kassiri Z, Zhong J, Guo D, et al. Loss of angiotensin-converting
enzyme 2 accelerated maladaptive left ventricular remodelling in
response to myocardial infarction. Circ Heart Fail 2009; 2:446-455.
17. Zeng Z, Sha T, Zhang Y et al. Hypertension in patients hospitalized
with COVID-19 in Wuhan, China: A single-center retrospective
observational study. medRxiv preprint doi:
https://doi.org/10.1101/2020.04.06.20054825
18. Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II
receptor blockers associated to mitigation of disease severity in
elderly COVID-19 patients. medRxiv 2020.03.20.20039586; doi:
https//doi.org/10.1101/2020.03.20.20039586.
19. Yang G, Tan Z, Lou Z et al. Angiotensin II Receptor Blockers and
Angiotensin-Converting Enzyme Inhibitors Usage is Associated with
Improved Inflammatory Status and Clinical Outcomes in COVID-Patients
With Hypertension. . medRxiv preprint doi:
https://doi.org/10.1101/2020.03.31.20038935
20. Bean D, Kraljevic Z, Searle T, et al. Treatment with ACE-inhibitors
is associated with less severe disease with SARS-COVID-19 infection in a
multi-sile UK acute Hospital Trust.
medRxiv 2020.04.07.20056788; doi:
https//doi.org/10.1101/2020.04.07.20056788
21. Zhang P, Zhu L, Cai J et al. Association of Inpatient Use of
Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor
Blockers with Mortality Among Patients With Hypertension Hospitalized
With COVID-19. Circ Res. DOI: 10.1161/CIRCRESAHA.120.317134
22. Li J, Wang X, Chen J et al. Association of renin-angiotensin system
inhibitors with severity or risk of death in patients with hypertension
hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan,
China. JAMA Cardiol. (2020) doi:10.1001/jamacardio.2020.1624
23. Montecucco F, Pende A, Mach F. The Renin-Angiotensin System
Modulates Inflammatory Processes in Atherosclerosis: Evidence from Basic
Research and Clinical Studies. Mediators of Inflammation 2009,
doi:10.1155/2009/752406
24. Dandona P, Dhindsa S, Ghanim H. et al. Angiotensin II and
inflammation: the effect of angiotensin-converting enzyme inhibition and
angiotensin II receptor blockade. J Hum
Hypertens 21, 20–27 (2007).
https://doi.org/10.1038/sj.jhh.1002101
25. European Societies of Cardiology. Position statement of the ESC
Council on Hypertension on ACE-inhibitors and angiotensin receptor
blockers. March 13, 2020. Available at: https://www.escardio.
org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on
hyper tension-on-ace-inhibitors-and-ang.
26. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists
in COVID-19. March 17, 2020. Available at: https://www.acc.
org/latest-in-cardiology/ artic
les/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19.
27. A statement from the International Society of Hypertension on
COVID-19. March 16,2020. Available at:
https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/
28. Sekizawa K, Matsui T, Nakagawa T. ACE inhibitors and Pneumonia.
Lancet 1998, 352: 1069